Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 16:00:02 2024-06-17 EDT			Pre-market 08:06:18
146 ^USD	+0.28%		145.9	-0.04%

06-17	J&J: FDA application in lung cancer	CF
06-17	Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	06-17	BU
J&J commits five-year investment in Italian medicine manufacturing	06-17	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	06-17	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	06-17	AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	06-15	PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	06-14	PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	06-14	PU
That's Stentertainment	06-13	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	06-12	PU
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy	06-12	BU
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states	06-12	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Transcript	06-11	PU
ERISA Group Health Plans – The New Target In Fee Cases	06-11	AQ
Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	06-07	PU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	06-05	AQ
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	06-04	BU
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	06-04	PU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	06-04	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	06-03	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	06-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm